Alpha 2.0
Login Register
» Articles » PMID: 20557856

MYCN/MYC-mediated Drug Resistance Mechanisms in Neuroblastoma

Overview
Journal Int J Clin Pharmacol Ther
Specialty Pharmacology
Date 2010 Jun 19
PMID 20557856
Citations 9
Authors
S Gogolin
D Dreidax
G Becker
V Ehemann
M Schwab
F Westermann
Affiliations
Soon will be listed here.
Citing Articles

Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN.

Zhang X, Cong X, Jin X, Liu Y, Zhang T, Fan X Cell Death Dis. 2023; 14(8):504.

PMID: 37543638 PMC: 10404282. DOI: 10.1038/s41419-023-06030-5.

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.

Agarwal P, Glowacka A, Mahmoud L, Bazzar W, Larsson L, Alzrigat M Int J Mol Sci. 2023; 24(9).

PMID: 37175848 PMC: 10179553. DOI: 10.3390/ijms24098141.

ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo.

Yu Y, Zhao Y, Choi J, Shi Z, Guo L, Elizarraras J Cancers (Basel). 2022; 14(22).

PMID: 36428626 PMC: 9688897. DOI: 10.3390/cancers14225534.

A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.

Perri P, Ponzoni M, Corrias M, Ceccherini I, Candiani S, Bachetti T Cancers (Basel). 2021; 13(21).

PMID: 34771690 PMC: 8582685. DOI: 10.3390/cancers13215528.

The MYCN Protein in Health and Disease.

Ruiz-Perez M, Henley A, Arsenian-Henriksson M Genes (Basel). 2017; 8(4).

PMID: 28358317 PMC: 5406860. DOI: 10.3390/genes8040113.